Iovance Share Increase Proposal Weighs Dilution Risk Against TIL Growth Funding [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Iovance Biotherapeutics, listed as NasdaqGM:IOVA, has proposed a significant increase to its authorized common stock. Shareholders are scheduled to vote on the proposal at the company's upcoming annual meeting. The authorization change would give the company more flexibility for future equity issuances, subject to board approval. Iovance Biotherapeutics focuses on cell therapies targeting cancer, an area that often requires substantial capital for clinical development, manufacturing capacity, and potential commercialization. In this context, a move to expand the authorized share pool can be important for future financing options, business development deals, or employee equity plans. For investors, the key questions are why management wants this additional capacity now and how it might be used over time. The upcoming vote will shape Iovance Biotherapeutics' future capital structure, so it is worth understanding both the potential for dilution and the possible role of new capit
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026GlobeNewswire
- Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi Drug [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains? [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics (IOVA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $16.00 price target on the stock.MarketBeat
IOVA
Earnings
- 2/24/26 - Beat
IOVA
Sec Filings
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form DEF
- 4/17/26 - Form PRE
- IOVA's page on the SEC website